Measure of the circulating rate of IGFBP-3, GHBP, ghrelin and apelin.
Time frame · Before starting treatment (J0)
Measure of physical composition's variation.
Time frame · Before starting treatment (J0)
Measure of blood sugar level, H.G.P.O., and hyperglycaemia.
Time frame · Before starting treatment (J0)
Measure of the sensibility at the growth hormone in vitro, on fibroblasts and adipocytes obtained by biopsy.
Time frame · Before starting treatment (J0)
Measure of the circulating rate of IGFBP-3, GHBP, ghrelin and apelin.
Time frame · 3 months (M3)
Measure of the circulating rate of IGFBP-3, GHBP, ghrelin and apelin.
Time frame · 6 months (M6)
Measure of the circulating rate of IGFBP-3, GHBP, ghrelin and apelin.
Time frame · 1 year (M12)
Measure of physical composition's variation.
Time frame · 3 months (M3)
Measure of physical composition's variation.
Time frame · 6 months (M6)
Measure of physical composition's variation.
Time frame · 1 year (M12)
Measure of blood sugar level, H.G.P.O., and hyperglycaemia.
Time frame · 3 months (M3)
Measure of blood sugar level, H.G.P.O., and hyperglycaemia.
Time frame · 6 months (M6)
Measure of blood sugar level, H.G.P.O., and hyperglycaemia.
Time frame · 1 year (M12)
Measure of the sensibility at the growth hormone in vitro, on fibroblasts and adipocytes obtained by biopsy.
Time frame · 3 months (M3)
Measure of the sensibility at the growth hormone in vitro, on fibroblasts and adipocytes obtained by biopsy.
Time frame · 6 months (M6)
Measure of the sensibility at the growth hormone in vitro, on fibroblasts and adipocytes obtained by biopsy.
Time frame · 1 year (M12)